We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The dual antibody cocktail entered a phase 3 trial this week to assess its ability to prevent infection among people exposed to coronavirus patients. Read More
While several hydroxychloroquine trials in COVID-19 patients have been shuttered, a large study led by Michigan’s Henry Ford Health System (HFHS) has found that the antimalarial drug significantly cut death rates in hospitalized patients and could still hold promise as a COVID-19 treatment. Read More
Regeneron Pharmaceuticals has begun a phase 3 clinical trial in the U.S. of its antibody cocktail REGN-COV2 for the prevention of COVID-19 infections. Read More
The parallel use of human challenge trials and large-scale conventional trials could help accelerate the development of an effective vaccine for COVID-19, NIH vaccine experts say. Read More
Sanofi and Regeneron Pharmaceuticals have stopped a phase 3 clinical trial in the U.S. of their rheumatoid arthritis drug Kevzara (sarilumab) as a COVID-19 treatment after it failed to meet its primary endpoints. Read More